株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

前立腺癌治療の世界市場予測(2019年~2025年)

Global Prostate Cancer Therapeutics Market 2019-2025

発行 Orion Market Research Pvt Ltd 商品コード 920448
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
前立腺癌治療の世界市場予測(2019年~2025年) Global Prostate Cancer Therapeutics Market 2019-2025
出版日: 2019年12月20日 ページ情報: 英文
概要

世界の前立腺癌治療市場は、前立腺癌の発生率の上昇、堅実な研究開発の探求、助成金、および前立腺癌治療の代替案の発見のための投資により、楽観的な見通しとなっています。前立腺癌はアンドロゲン依存性の病気で、初期段階では薬と治療に反応しますが、後期には治療薬や他の治療法に耐性ができてきます。前立腺癌には、年齢、民族、家族歴および遺伝子、過体重または肥満、IGF-1(成長因子などのインスリン)、精管切除、および前立腺の炎症などの特定の原因があります。

当レポートでは、世界の前立腺癌治療薬市場について調査分析し、市場概要、市場決定要因、市場区分、競合情勢、地域別分析、主要企業などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

  • 調査方法とツール
  • 市場分析
    • セグメント別
    • 地域別

第2章 市場概要と考察

  • レポートの範囲
  • アナリストの考察と最新市場動向
    • 主な調査結果
    • 提言
    • 結論
  • 規則・規制

第3章 競争環境

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析
    • Sanofi S.A.
    • アステラス製薬
    • Bayer AG
    • Johnson&Johnson Services、Inc.
    • AstraZeneca PLC

第4章 市場決定要因

  • 成長要因
  • 阻害要因
  • 市場機会

第5章 市場セグメンテーション

  • 世界の前立腺癌治療市場:治療法別
    • ホルモン療法
    • 化学療法
    • 免疫療法
    • 放射線療法
    • 標的療法

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第7章 会社概要

  • Abbott Laboratories, Inc.
  • AbbVie, Inc.
  • Amgen, Inc.
  • Anixa Biosciences, Inc.
  • アステラス製薬
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • Decipher Biosciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ferring B.V.
  • General Electric Co.
  • GlaxoSmithKline PLC
  • Ipsen Group
  • Johnson & Johnson Services, Inc.
  • MDNA Life Sciences, Inc.
  • Merck KGaA
  • miR Scientific, LLC
  • Myriad Genetics, Inc.
  • Nanostics Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Siemens Healthcare AG
図表

List of Tables

  • 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 2. GLOBAL HORMONAL THERAPY FOR PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL CHEMOTHERAPY FOR PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL IMMUNOTHERAPY FOR PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL RADIATION THERAPY FOR PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 6. GLOBAL TARGETED THERAPY FOR PROSTATE CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 8. NORTH AMERICAN PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 9. NORTH AMERICAN PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 10. EUROPEAN PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 11. EUROPEAN PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 12. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 13. ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
  • 14. REST OF THE WORLD PROSTATE CANCER THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)

List of Figures

  • 1. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SHARE BY THERAPY, 2018 VS 2025 (%)
  • 2. GLOBAL PROSTATE CANCER THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 3. US PROSTATE CANCER THERAPEUTICS SIZE, 2018-2025 ($ MILLION)
  • 4. CANADA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. UK PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. FRANCE PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. GERMANY PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. ITALY PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. SPAIN PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. ROE PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. INDIA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. CHINA PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. JAPAN PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. REST OF ASIA-PACIFIC PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF THE WORLD PROSTATE CANCER THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
目次
Product Code: OMR2020060

Prostate Cancer Therapeutics Market Size, Share & Trends Analysis Report, By Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, and Targeted Therapy) and Forecast 2019-2025

The global prostate cancer therapeutics market has witnessed optimistic growth owing to the rising incidence rate of prostate cancer, robust R&D exploration and grants and investment for discovery of potential alternatives for prostate cancer treatment. Prostate cancer is an androgen-dependent disease that responds to medicine and treatment in the initial stages, however, in the later stages, it becomes resistant to therapies and other treatments. There are certain causes of prostate cancer which includes age, ethnicity, family history and genes, being overweight or obese, IGF-1 (Insulin such as growth factor), vasectomy, and inflammation of the prostate and others.

The US contributes highest in the prostate cancer treatment market owing to the significant prevalence of prostate cancer and the presence of well-developed healthcare infrastructure in the country. The rising adoption of minimally invasive surgeries is contributing to the demand for laparoscopic, brachytherapy, cryosurgical ablation and robotic radical prostatectomy for the treatment of prostate cancer. Other factors that are boosting the global prostate cancer therapeutics market includes R&D, rise in grants and funding, increasing adoption of personalized medicines, growing pharmaceutical industries and others. Further, successful clinical trials and FDA approval will influence the market growth in the near future.

North America and Europe have considerable contribution in the growth of the market followed by Asia-Pacific region. The key driving forces include rising incidence and prevalence of prostate cancer and adoption of innovative surgeries and treatment across the globe. Economies such as China, India, Japan, and South Korea have huge population of cancer patients. Technological advancement, innovation, and improved healthcare spending are anticipated to drive the growth of Asia-Pacific region. Improved standard of living, infrastructural development, and favorable government policies are some other factors that spur the regional growth of the market.

Some of the key players contributing significantly in the growth of prostate cancer therapeutics market include Sanofi S.A., Bayer AG, Astellas Pharma Inc., Merck KGaA, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., and AstraZeneca PLC. The market players are constantly focusing on product launch, R&D, partnerships and collaborations, and mergers and acquisitions.

Research Methodology

The market study of the global prostate cancer therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Authentic public databases such as the American Cancer Society, and the National Institute of Health.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalogue.

The report is intended for cancer diagnostics, treatment and therapies providers, cancer drug manufacturers, pharmaceutical companies, healthcare organization, existing companies, and new entrants, potential investors and venture capitalists, research organizations, and government agencies and regulatory bodies for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, products offered by the company, and future market opportunity. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Prostate Cancer Therapeutics Market Research and Analysis, By Therapy

The Report covers:

  • Comprehensive research methodology of the global prostate cancer therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global prostate cancer therapeutics market.
  • Insights about market determinants which are stimulating the global prostate cancer therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 1.2.3. Key Findings
    • 1.2.4. Recommendations
    • 1.2.5. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Sanofi S.A.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Astellas Pharma, Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Bayer AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Johnson & Johnson Services, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. AstraZeneca PLC
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Prostate Cancer Therapeutics Market by Therapy
    • 5.1.1. Hormonal Therapy
    • 5.1.2. Chemotherapy
    • 5.1.3. Immunotherapy
    • 5.1.4. Radiation Therapy
    • 5.1.5. Targeted Therapy

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories, Inc.
  • 7.2. AbbVie, Inc.
  • 7.3. Amgen, Inc.
  • 7.4. Anixa Biosciences, Inc.
  • 7.5. Astellas Pharma, Inc.
  • 7.6. AstraZeneca PLC
  • 7.7. Bavarian Nordic A/S
  • 7.8. Bayer AG
  • 7.9. Bristol-Myers Squibb Co.
  • 7.10. Decipher Biosciences, Inc.
  • 7.11. F. Hoffmann-La Roche Ltd.
  • 7.12. Ferring B.V.
  • 7.13. General Electric Co.
  • 7.14. GlaxoSmithKline PLC
  • 7.15. Ipsen Group
  • 7.16. Johnson & Johnson Services, Inc.
  • 7.17. MDNA Life Sciences, Inc.
  • 7.18. Merck KGaA
  • 7.19. miR Scientific, LLC
  • 7.20. Myriad Genetics, Inc.
  • 7.21. Nanostics Inc.
  • 7.22. Novartis AG
  • 7.23. Pfizer, Inc.
  • 7.24. Sanofi S.A.
  • 7.25. Siemens Healthcare AG